Cell No. : Cell Name
RCB2229 : HS-Os-1
update : 2024/09/05
|
| Comment | Human cell line derived from osteosarcoma. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Sonobe, Hiroshi
|
| Originator |
Sonobe, Hiroshi
|
| Year of deposit |
2002
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
11 years
|
| Tissue |
left humerus
|
| Disease name |
osteosarcoma
|
| Classification |
cancer
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_8716
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
3
|
| User's Publication |
8
|
| Reference |
|
3833
Ogawa Y, Takahashi T, Kobayashi T, Kariya S, Nishioka A, Mizobuchi H, Noguchi M, Hamasato S, Tani T, Seguchi H, Yoshida S, Sonobe H.
Mechanism of hydrogen peroxide-induced apoptosis of the human osteosarcoma cell line HS-Os-1
Int J Mol Med
2003
12(4):459-63
PubMed ID: 12964019
|
|
3844
Ogawa Y, Takahashi T, Kobayashi T, Kariya S, Nishioka A, Ohnishi T, Saibara T, Hamasato S, Tani T, Seguchi H, Yoshida S, Sonobe H.
Apoptotic-resistance of the human osteosarcoma cell line HS-Os-1 to irradiation is converted to apoptotic-susceptibility by hydrogen peroxide: a potent role of hydrogen peroxide as a new radiosensitizer
Int J Mol Med
2003
12(6):845-50
PubMed ID: 14612955
|
|
3500
Sonobe H, Mizobuchi H, Manabe Y, Furihata M, Iwata J, Hikita T, Oka T, Ohtsuki Y, Goto T.
Morphological characterization of a newly established human osteosarcoma cell line, HS-Os-1, revealing its distinct osteoblastic nature.
Virchows Arch B Cell Pathol Incl Mol Pathol
1991
60(3):181-7
PubMed ID: 1679269
DOI: 10.1007/BF02899545
|
| User's Publication |
|
19614
Omori K, Otani S, Date Y, Ueno T, Ito T, Umeda M, Ito K.
C/ebpα represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development
Oncogene
2023
42(33):2485-2494
PubMed ID: 37402881
DOI: 10.1038/s41388-023-02761-z
|
|
12455
Moritake H, Saito Y, Sawa D, Sameshima N, Yamada A, Kinoshita M, Kamimura S, Konomoto T, Nunoi H.
TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma
Cancer Med
2019
8(18):7809-7821
PubMed ID: 31692287
DOI: 10.1002/cam4.2647
|
|
10919
Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma
Integr Mol Med
2016
3: 755-760
DOI: 10.15761/IMM.1000239
|
|
7459
Tsuru A, Setoguchi T, Matsunoshita Y, Nagao-Kitamoto H, Nagano S, Yokouchi M, Maeda S, Ishidou Y, Yamamoto T, Komiya S.
Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression.
Br. J. Cancer
2015
112:1232-40
PubMed ID: 25742474
DOI: 10.1038/bjc.2015.84
|
|
3136
Nagao-Kitamoto H, Setoguchi T, Kitamoto S, Nakamura S, Tsuru A, Nagata M, Nagano S, Ishidou Y, Yokouchi M, Kitajima S, Yoshioka T, Maeda S, Yonezawa S, Komiya S.
Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion
Cancer Lett
2015
356(2 Pt B):855-61
PubMed ID: 25449781
DOI: 10.1016/j.canlet.2014.10.042
|
|
17454
Nagao-Kitamoto H, Nagata M, Nagano S, Kitamoto S, Ishidou Y, Yamamoto T, Nakamura S, Tsuru A, Abematsu M, Fujimoto Y, Yokouchi M, Kitajima S, Yoshioka T, Maeda S, Yonezawa S, Komiya S, Setoguchi T.
GLI2 is a novel therapeutic target for metastasis of osteosarcoma
Int J Cancer
2015
136(6):1276-84
PubMed ID: 25082385
DOI: 10.1002/ijc.29107
|
|
6428
Arai K, Sakamoto R, Kubota D, Kondo T.
Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.
Proteomics
2013
13(15):2351-60
PubMed ID: 23712969
DOI: 10.1002/pmic.201300053
|
|
18251
Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA.
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling
Int J Oncol
2011
39(1):73-89
PubMed ID: 21537839
DOI: 10.3892/ijo.2011.1020
|
Back
Top
CELL BANK Website